Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GRF312
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Grifols International
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Clears IND for Immunoglobulin Eye Drops to Treat Dry Eye Disease
Details : Immunoglobulin ophthalmic solution, GRF312, is being investigated for the treatment of patients with dry eye disease (DED).
Product Name : GRF312
Product Type : Protein
Upfront Cash : Inapplicable
May 21, 2025
Lead Product(s) : GRF312
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Grifols International
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SLG-100
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Grifols International
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Grifols will develop and commercialise immunoglobulin eye drops, SLG-100, for dry eye disease. An immunoglobulin eye drop is a biologic drug that contains naturally occurring functional antibodies generated from human plasma collected from thousands of h...
Product Name : SLG-100
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 03, 2023
Lead Product(s) : SLG-100
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Grifols International
Deal Size : Undisclosed
Deal Type : Collaboration